RNA Quote, Financials, Valuation and Earnings

Dyne Therapeutics has a net margin of -3441.7% compared to Avidity Biosciences's net margin of --. Avidity Biosciences's return on equity of -30.66% beat Dyne Therapeutics's return on equity of --.

Avidity Biosciences has a consensus price target of $68.27, signalling upside risk potential of 114.56%. On the other hand Dyne Therapeutics has an analysts' consensus of -- which suggests that it could grow by 110.16%. Given that Avidity Biosciences has higher upside potential than Dyne Therapeutics, analysts believe Avidity Biosciences is more attractive than Dyne Therapeutics.

Avidity Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Dyne Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Avidity Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dyne Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Avidity Biosciences pays -- of its earnings as a dividend. Dyne Therapeutics pays out -- of its earnings as a dividend.

Avidity Biosciences quarterly revenues are $2.3M, which are larger than Dyne Therapeutics quarterly revenues of --. Avidity Biosciences's net income of -$80.4M is higher than Dyne Therapeutics's net income of -$97.1M. Notably, Avidity Biosciences's price-to-earnings ratio is -- while Dyne Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avidity Biosciences is 309.49x versus -- for Dyne Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of -3441.7% compared to Avidity Biosciences's net margin of 7.2%. Avidity Biosciences's return on equity of -30.66% beat Sarepta Therapeutics's return on equity of 12.48%.

Avidity Biosciences has a consensus price target of $68.27, signalling upside risk potential of 114.56%. On the other hand Sarepta Therapeutics has an analysts' consensus of $185.10 which suggests that it could grow by 55.59%. Given that Avidity Biosciences has higher upside potential than Sarepta Therapeutics, analysts believe Avidity Biosciences is more attractive than Sarepta Therapeutics.

Avidity Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.767, suggesting its less volatile than the S&P 500 by 23.328%.

Avidity Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Avidity Biosciences pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

Avidity Biosciences quarterly revenues are $2.3M, which are smaller than Sarepta Therapeutics quarterly revenues of $467.2M. Avidity Biosciences's net income of -$80.4M is lower than Sarepta Therapeutics's net income of $33.6M. Notably, Avidity Biosciences's price-to-earnings ratio is -- while Sarepta Therapeutics's PE ratio is 77.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avidity Biosciences is 309.49x versus 7.30x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Entrada Therapeutics has a net margin of -3441.7% compared to Avidity Biosciences's net margin of -71.7%. Avidity Biosciences's return on equity of -30.66% beat Entrada Therapeutics's return on equity of 17.06%.

Avidity Biosciences has a consensus price target of $68.27, signalling upside risk potential of 114.56%. On the other hand Entrada Therapeutics has an analysts' consensus of -- which suggests that it could grow by 50.16%. Given that Avidity Biosciences has higher upside potential than Entrada Therapeutics, analysts believe Avidity Biosciences is more attractive than Entrada Therapeutics.

Avidity Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Entrada Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Avidity Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Entrada Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Avidity Biosciences pays -- of its earnings as a dividend. Entrada Therapeutics pays out -- of its earnings as a dividend.

Avidity Biosciences quarterly revenues are $2.3M, which are smaller than Entrada Therapeutics quarterly revenues of $19.6M. Avidity Biosciences's net income of -$80.4M is lower than Entrada Therapeutics's net income of -$14M. Notably, Avidity Biosciences's price-to-earnings ratio is -- while Entrada Therapeutics's PE ratio is 11.07x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avidity Biosciences is 309.49x versus 2.95x for Entrada Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of -3441.7% compared to Avidity Biosciences's net margin of 37.71%. Avidity Biosciences's return on equity of -30.66% beat Vertex Pharmaceuticals's return on equity of -2.89%.

Avidity Biosciences has a consensus price target of $68.27, signalling upside risk potential of 114.56%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $498.37 which suggests that it could grow by 25.42%. Given that Avidity Biosciences has higher upside potential than Vertex Pharmaceuticals, analysts believe Avidity Biosciences is more attractive than Vertex Pharmaceuticals.

Avidity Biosciences has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.364, suggesting its less volatile than the S&P 500 by 63.631%.

Avidity Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Avidity Biosciences pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

Avidity Biosciences quarterly revenues are $2.3M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.8B. Avidity Biosciences's net income of -$80.4M is lower than Vertex Pharmaceuticals's net income of $1B. Notably, Avidity Biosciences's price-to-earnings ratio is -- while Vertex Pharmaceuticals's PE ratio is 25.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Avidity Biosciences is 309.49x versus 9.73x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.